New Mexico Technical Research Foundation

New Mexico Tech Research Foundation

New Mexico Tech University Research Park Corporation

Texas State University

Leiden University

Alexander Kornienko

Snezna Rogelj

Liliya Vladlenovna Frolova

Danielle Nicole Turner

Kailee Zingler

Igor V Magedov

Leslie D Edwards

Cody Champion

Sean Henry

Vincent Van Rixel

Tania Betan-Court

Alexander V Akensov

Sylvestre Bonnet

Gabriel Avilucea

Igov V Magedov

Described herein is photocaging methodology using ruthenium (II) complexes with 7-deazahypoxanthine-based anticancer agents. Specifically, 7-deazahypoxanthines are converted into photoactivatable chemotherapeutic agents for the controlled release of these toxic agents selectively into tumor tissue upon irradiation with light.

Photoactivatable cancer prodrug

The present disclosure describes a method to treat conditions, including cancer, using compounds that can target resistant cancer cells. The compounds of the invention can decrease the rate of proliferation of drug-resistant cancer cells, such as glioma, lung cancer, and uterine sarcoma.

Methods for treatment of resistant cancer

The present disclosure describes a method to treat conditions, including bacterial infections and cancer, using a photosensitive compound that, upon exposure to white light, can be activated. The photosensitive compound can also interact synergistically with antibiotics used concomitantly to kill drug-resistant bacteria. The photosensitive compounds can also be used to inhibit the proliferation of cancer cells.

Antibiotic sensitivity-restoring and photosensitive agents

A compound having the Formula as follows: wherein R, Rand Rare selected from hydrogen, aryl, fused aryl, heteroaryl, saturated carbocylclic, partially saturated carbocyclic, saturated heterocyclic, partially saturated heterocyclic, Calkyl, haloalkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, alkenylalkyl, alkynylalkyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitroalkyl, cyanoalkyl, acetamidoalkyl, and acyloxyalkyl. A process for the preparation thereof is also provided.

Synthetic rigidin analogues as anticancer agents, salts, solvates and prodrugs thereof, and method of producing same

A pharmaceutical composition, a method of producing same, and a method of providing cancer therapy therein comprising a pharmaceutically acceptable excipient or carrier and a compound Formula 3 as follows: or a pharmaceutically acceptable salt or prodrug thereof, wherein:

Treatment of drug-resistant cancer with 2-aryl-2-(3-indolyl) acetohydroxamates

A compound having the Formula I as follows: 

A pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier and a compound Formula I: or a pharmaceutically acceptable salt or prodrug thereof.

Pyrano [3,2-C] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof

Growing community of inventors

San Marcos, TX, United States of America

Alexander Kornienko